Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Chairman operating in the Medical space. If you think a Chairman is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
George Archos
Co-Founder, Chairman and CEO of Verano Holdings
George Archos is the founder & CEO of Verano Holdings. He is a logistics and operations guru. Building on his extensive experience in coordinating complex freight delivery operations, as well as designing and operating highly-successful restaurants, George entered the cannabis industry in 2014 when he founded Ataraxia Grow and Labs in Illinois and was the first to receive authorization to grow medical cannabis out of 21 recipients of the coveted medical licenses. George’s diligence, perseverance, and tireless work ethic have made him one of the cannabis industry’s most successful entrepreneurs. Leveraging his unparalleled devotion to quality and a unique results-oriented approach to the cannabis industry, George has overseen the development of some of cannabis’s most highly-coveted operations and brands. George’s restaurants across the Chicagoland area, including Wildberry Pancakes & Café, Westwood Tavern & Tap and the Scout Waterhouse & Kitchen, all bear the imprint of his relentless devotion to quality and unrivaled customer service, earning him multiple awards and recognition. George’s unique experience, his admirable drive, and his unrelenting commitment to quality, coupled with his capacity to establish, build, and effectively run multi-jurisdictional companies, are an asset to Verano Holdings.
Follow George Archos:
About Verano Holdings: Verano is a vertically integrated, multi-state cannabis operator.
Jonathan Milner
Chairman & Co-founder of Axol Bioscience
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon Discovery Group plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Follow Jonathan Milner:
About Abcam, Axol Bioscience, Milner Centre for Evolution, Natural History Museum, SyndicateRoom: Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers.
Aaron Kaufman
CEO & Chairman of OpenMed
Follow Aaron Kaufman:
About : OpenMed is a digital innovator in closing care gaps, enabling access to care, and supporting real-time collaboration.
Paul Bisaro
Executive Chairman of Allergan
Paul Bisaro currently serves as Executive Chairman of Allergan and the Company’s Board of Directors. He served as the Chief Executive Officer of Actavis from September 2007 to July 2014. Prior to joining Actavis (then Watson), he was President and Chief Operating Officer of Barr Pharmaceuticals, Inc. (“Barr”) from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development at Barr. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan in 1983 and a Juris Doctor from Catholic University of America in Washington, D.C. in 1989.
Follow Paul Bisaro:
About Allergan: Allergan is a global pharmaceutical company.
Brenton Saunders
Chairman, President and Chief Executive Officer of Allergan
Brent Saunders is Chief Executive Officer and President of Allergan plc (formerly Actavis plc). Brenton previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Member of the Board of Directors at Forest since 2011. Brenton has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Prior to Forest, Brenton was Chief Executive Officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Brenton also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Brenton was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, Brenton was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Brenton began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Brenton serves on the Board of Trustees of the University of Pittsburgh. Brenton is also the former Chairman of the New York chapter of the American Heart Association. Brenton is a Member of the Business Council and PhRMA. Brenton earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his Bachelor’s degree from the University of Pittsburgh.
Follow Brenton Saunders:
About Allergan, Cisco: Allergan is a global pharmaceutical company.
Sam Santhosh
Founder Chairman & Global CEO of MedGenome
Sam Santhosh is the Founder and CEO of MedGenome. He has been an entrepreneur, with over 20 years of experience in the software industry. Currently, he is at the helm of affairs as CEO and promoter of MedGenome Labs Pvt Ltd. Sam sits on the board of a number of companies, both in the US and India. In this role he advises, guides and mentors companies to help them grow and realize their true potential. Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992 – Feb 2012. He founded Calsoft in 1992 and under Sam’s vision, Calsoft rapidly grew from a niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8 countries. Sam took Calsoft Public and the company is listed the in Indian Stock Exchanges. Sam oversaw the growth of Calsoft in all key areas – Finance, Strategy, Customer Acquisition, and inorganic growth through eight acquisitions including companies in the U.S, UK, Japan, and India. He has been constantly retooling himself and has attended various training programs in different U.S universities including MIT. In 2010, he completed the Executive Education program at the Singularity University in Sunnyvale, California. Sam has an engineering degree and an MBA (majoring in Management Information Systems) from India’s premier institute, IIM Calcutta.
Follow Sam Santhosh:
About Agrigenome, MedGenome: MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Jeff Aronin
Chairman and Co-founder of Evozyne
Jeffrey S. Aronin has decades of experience developing innovative global biotech and health care companies. His keen ability to identify ideas and scientific innovations with the highest potential to change lives and improve the world has made Mr. Aronin one of the most impactful and successful leaders in the life science sector. As an entrepreneur and scientific visionary, with a focus on addressing unmet patient and societal needs, Mr. Aronin has received U.S. Food and Drug Administration (FDA) approval of numerous new medicines and technologies. His companies are renowned for advancing science, with a record number of breakthroughs helping patients, and economic engines, having created thousands of job opportunities throughout the world. As founder of Paragon Biosciences, Mr. Aronin serves as its chairman and chief executive officer. Paragon is a life science innovator that creates, invests in, and builds bioscience companies in biotechnology, gene therapy and synthetic biology. Paragon Biosciences founded Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, and Skyline Biosciences, and maintains a consistent flow of incubating companies created and supported by the Paragon Innovation Capital™ model. Since 2017, Paragon and its partners have invested more than $1 billion in its portfolio companies and expects ongoing investments of up to $500 million annually to address unmet need through life science breakthroughs. Throughout his career, Mr. Aronin has received numerous distinctions and honors for his entrepreneurship and dedication to life sciences. In 2020, he was named as one of the Top 10 Inspiring CEOs by Insights Success magazine. In 2018, he was named Innovator of the Year by Best in Biz Awards for his lifelong commitment to developing medicines for severe diseases. That same year, Insights Care named Mr. Aronin one of the 20 Most Influential Leaders in Healthcare. He was awarded the Weizmann Leadership Award in recognition of his work to improve patients’ lives through advancements in science and technology. Mr. Aronin has been inducted into the Chicago Entrepreneur Hall of Fame and was also honored with the EY Entrepreneur of the Year Award. Outside of Paragon, Mr. Aronin devotes his talents to civic and philanthropic endeavors. As founder and chairman of MATTER – a health-technology incubator to support innovators – Mr. Aronin has led one of Chicago’s most remarkable, philanthropic venture-innovation successes, with more than 200 healthcare companies at any one time, more than 60 corporate sponsors, and more than $1.7 billion in deals since 2015. He serves on several corporate and civic boards including Discover Financial Services and The Aspen Institute and is a member of The Commercial Club of Chicago. As a believer in education as a change agent, Mr. Aronin is a mentor to students and young professionals and is a frequent lecturer at the University of Chicago’s Booth School of Business and Northwestern University’s Kellogg School of Business.
Follow Jeff Aronin:
About Castle Creek Biosciences, Castle Creek Biosciences, Circ, Emalex Biosciences, Inc., Evozyne, Harmony Biosciences, Harmony Biosciences, Ovation Pharmaceuticals, Paragon Biosciences, Paragon Biosciences, Paragon Health Capital, Paragon Pharmaceuticals, Qlarity Imaging, Skyline Biosciences, Skyline Biosciences, The Aspen Institute, The University of Chicago Booth School of Business: Evozyne is a biotechnology company that specializes in protein design and molecular scale.
Richard Burke
Non-Executive Chairman of the Board of Directors of UnitedHealth Group
Richard Burke is a Non-Executive Chairman of the Board of Directors at UnitedHealth Group.
Follow Richard Burke:
About : UnitedHealth Group is a healthcare company that offers insurance products and services for everyone.
Isaiah Harris
Chairman & Board Member of Cigna
Isaiah Harris is the Chairman of the Board of Directors at Cigna since December 2009 and served as Vice-Chairman of the Board of Directors from July 2009 through December 2009. Isaiah has served as an Independent Trustee of Wells Fargo Advantage Funds (a provider of mutual funds) since 2008 and served as a Member of the Board of Directors at Deluxe Corporation (a provider of customized products and services including financial services and direct checks) from 2004 until 2011. Before his direct role overseeing advertising and publishing, Isaiah served as President of BellSouth Enterprises for BellSouth Corp. in Atlanta, Georgia. Isaiah was responsible for BellSouth’s European and Latin American operations and BellSouth’s Advertising and Publishing Company. Isaiah was also Co-Chairman of BellSouth’s Diversity Council. Before the BellSouth Enterprises role, Isaiah served three years as President of BellSouth Consumer Services, with responsibility for the strategic marketing, sales and customer service direction of BellSouth’s largest customer unit. Isaiah joined BellSouth in 1997 as BellSouth Telecommunications’ Chief Financial Officer and assumed the role of Corporate Vice President of Finance before moving to Consumer Services. A native of West Memphis, Arkansas, Isaiah holds a Bachelor of Science degree from Iowa State University and is a Certified Public Accountant. Isaiah has also completed the University of Minnesota executive MBA Program. Isaiah was nominated as NYSE 2014 Chairman of the Year and was recognized by the Outstanding Directors Exchange as a 2010 Outstanding Director.
Follow Isaiah Harris:
About : CIGNA Corporation operates as a health service company that helps people to improve the health, well-being, and peace of mind.
Mingzhe Ma
Chairman and CEO of Ping An
Mingzhe Ma is the founder of the Company. Mingzhe Ma founded Ping An Insurance Company in March 1988, and is the current Chairman and CEO of the Company. Since the establishment of the Company, Mingzhe Ma has served as President, Director, Chairman and CEO of the Company, and has been in charge of operations and management of the Company. Before establishing the Company, Mingzhe Ma was Deputy Manager of China Merchants Shekou Industrial Zone Social Insurance Company. Mingzhe Ma has a doctor’s degree in money and banking from Zhongnan University of Economics and Law (previously Zhongnan University of Economics).
Follow Mingzhe Ma:
About Ping An, Ping An Healthcare Management: Ping An Insurance Company is a holding company deals with insurance, banking, and financial service.
Mark Bertolini
Chairman and Chief Executive Officer of Aetna
Mark Bertolini is Chairman, Chief Executive Officer and President of Aetna, a Fortune 100 diversified health care benefits company with more than $47.2 billion in 2013 revenue. Aetna serves an estimated 44 million people with information and resources to help them make better informed decisions about their health care and has operations in North America, Asia, Europe and the Middle East. Bertolini assumed the role of CEO on November 29, 2010 and of Chairman on April 8, 2011. Bertolini joined Aetna in 2003 as head of Aetna’s Specialty Products. In July 2007, he was named president, responsible for all of Aetna’s businesses and operations across the company’s broad range of health care products and related services – including medical, pharmacy, dental, behavioral health, group life and disability plans, as well as medical management capabilities and health care management services for Medicaid plans. Prior to serving as Aetna’s president, Bertolini was executive vice president and head of Aetna’s regional businesses, which included the company’s individual, retiree, small group and middle market segments, as well as numerous product, network and service areas. Recognized as an accessible, forward-thinking and solutions-oriented leader, Bertolini is actively engaged in the national dialogue on health care reform, meeting regularly with state and federal policymakers to advocate for measures that increase access, lower costs and improve quality of health care. He is a strong advocate of market-based solutions, the expansion and use of health information technology, and the sustainability of the employer-based system. Firmly committed to diversity and inclusion, Bertolini also serves as the company’s executive sponsor for diversity, participates in several Aetna employee resource groups, and maintains a blog to communicate with employees. Among his civic activities, Bertolini serves on the Board of Directors of the U.S.-China Business Council, the Hole in the Wall Gang Camp, an organization founded by Paul Newman that serves children with cancer and other serious illnesses, and FIDELCO, an organization that breeds and trains guide dogs for the visually disabled. In 2009, he was elected the first straight ally board member of the National Gay and Lesbian Chamber of Commerce. Bertolini has been honored for his leadership by numerous universities and organizations, including the National Italian American Foundation, Outward Bound, the National Kidney Registry, Out & Equal Workplace Advocates, the Quinnipiac University Business School, and Wayne State University School of Business. Prior to joining Aetna, Bertolini held executive positions at Cigna, NYLCare Health Plans, and SelectCare, Inc., where he served as president and chief executive officer. Born and raised in Detroit, Bertolini held various jobs throughout high school and college, including assembly work at a Ford Motor Company plant and various caregiver roles in health care delivery.Bertolini is a spinal cord injury survivor and is partially disabled as the result of a severe skiing accident in 2004. In 2007, Bertolini donated a kidney to his son. His previous work and personal experiences with the health care system are foundational to his dedication to improving the patient experience and addressing the longstanding challenges facing the U.S. health care system. Bertolini holds an undergraduate degree in business administration/finance from Wayne State University and a MBA in finance from Cornell University.
Follow Mark Bertolini:
About Aetna: Aetna a diversified health care benefits company, provides individuals and many others with innovative benefits, products, and services.
Shane J Schaffer
Chairman and CEO of Cingulate Therapeutics
Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is an 18-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions of increasing responsibility at Pfizer, Novartis and Sanofi (including predecessor companies). Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products. Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.
Follow Shane J Schaffer:
About Cingulate Therapeutics: Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.
Martin Shkreli
Founder & Executive Chairman of Turing Pharmaceuticals
Martin Shkreli is the founder and CEO of Turing Pharmaceuticals. He is the founder of Retrophin, LLC (the predecessor of Retrophin, Inc.) and former President of Retrophin, Inc. since its formation. Martin Shkreli is also the founder and managing partner of MSMB Capital Management, a New York hedge fund firm founded in 2006 that manages a variety of partnerships. Prior to MSMB, Martin Shkreli was employed at Intrepid Capital Management from 2004 to 2006 and previously at Cramer Berkowitz & Co, both of which are hedge fund firms based in New York. Martin Shkreli is an experienced biotechnology and pharmaceutical industry investor, particularly in businesses with orphan drugs. Martin Shkreli received his BBA from Baruch College.
Follow Martin Shkreli:
About Shkreli Foundation, Turing Pharmaceuticals: Turing Pharmaceuticals is a biopharmaceutical company focusing on patients with unmet medical needs.
James C. Katzaroff
CEO, Chairman and Founder of Vivos Inc
A serial entrepreneur who started his first company importing minerals and pewter from Brazil while in high school in southern California, Mr. Katzaroff is constantly searching for outstanding opportunities. Hired straight out of college Mr. Katzaroff was a financial consultant for Wall Street firms Bateman Eichler, Smith Barney and EFHutton. Since 1990, he has been responsible for corporate engineering, senior-level corporate strategy, fostering investment bank relationships, and has served as a senior financial advisor for numerous start-ups and development stage companies. A strong desire to make an unshakable impact in the fight against cancer led Mr. Katzaroff to found AMI in 2006.
Follow James C. Katzaroff:
About Vivos Inc: Vivos Inc develops manufacturing equipments for the production of medical isotopes used in diagnosis and treatment of diseases.
Mark McManus, Jr
Founder and Chairman of The Healing Notes Foundation
Mark McManus, Jr. is President and Chief Executive Officer at NH Learning Solutions. A veteran of the computer training industry for more than 20 years, Mark is responsible for the company’s vision, financial performance, personnel, and organizational development. He has received a variety of awards in recognition of his numerous accomplishments. He was awarded the prestigious New Horizons President’s Cup award in 1997, the Circle of Excellence in 2000, and the New Horizons Lifetime Achievement Award in 2007. He has also received 10 North American “Franchise of the Year” awards over the past 15 years for the business performance within the Detroit, MI market. In addition, he was named one of Crain’s Detroit Business’ “40 under 40” in 1998, which recognized young, successful executives in Michigan. Mark is a member of the Young Presidents Organization Greater Detroit Chapter, as well as a member of the Franchise Advisory Committee (FAC) for New Horizons Computer Learning Centers.
Follow Mark McManus, Jr:
About Intellezy, NHLearning Solutions, The Healing Notes Foundation: The Healing Notes Foundation helps children and families cope with sickness and hospitalization by providing music therapy services.
Edward M. Boyle
Chairman of ClearFlow
Follow Edward M. Boyle:
About ClearFlow, VenX Medical: ClearFlow is a medical device company developing technologies to solve clinical problems associated with obstructed catheters.
Jeff Dachis
Founder, Chairman & CEO of OneDrop
Follow Jeff Dachis:
About OneDrop: One Drop is a diabetes management platform that helps people navigate diabetes together.
Gino Volpacchio
Chairman and CEO of PetVet Care Centers
Gino has extensive leadership experience in the pet care industry, and founded PetVet Care Centers in 2012. He is the consummate expert at putting together hospital acquisitions that provide maximum benefits to both sellers and buyers—every time.
Follow Gino Volpacchio:
About PetVet Care Centers: PetVet Care Centers is an operator of specialty and general practice animal hospitals in the United States.
Vivek Kopparthi
CEO, Co-Founder & Executive Chairman of NeoLight
Vivek Kopparthi is Co-founder & CEO of NeoLight, a lean medical device start-up developing a disruptive technology to treat Jaundice in infants.
Follow Vivek Kopparthi:
About NeoLight, PriZm Therapeutics: Neolight is a medical device company that develops phototherapy beds to cure jaundice in pre-term and full term babies.
Yulun Wang
Founder, Chairman & Chief Innovation Officer of InTouch Health
Yulun Wang, Chairman, Founder & Chief Innovation Officer, InTouch Health, Inc. Dr. Wang founded InTouch Health in 2002, and served as Chairman & CEO until 2016, when he assumed the position of Chairman and Chief Innovation Officer. InTouch Health is a pioneering and market leading telehealth company that enables patients to receive clinical care from specialists at a distance. InTouch has received numerous awards including Deloitte’s Technology Fast 500 Award and Inc Magazine’s Inc 500 award as one of the fastest growing companies in America. Previous to InTouch, Dr. Wang founded Computer Motion in 1990, the company which pioneered surgical robotics. He was the principal architect and inventor of the voice-controlled robotic arm called AESOP, the first FDA-cleared surgical robot, as well as the ZEUS robotic surgical system, which performed the world’s first transatlantic surgery. Computer Motion IPO’d in 1997 and merged with Intuitive Surgical (NASD: ISRG) in 2003 for one third of the resulting company. Dr. Wang is author to more than 50 technical publications and inventor on over 100 patents.
Follow Yulun Wang:
About InTouch Health: InTouch Health is the leader in Acute Care Telemedicine solutions.
Rishi Shah
Founder & Chairman of Outcome Health
Rishi Shah is the Founder and Chairman at Outcome Health.
Follow Rishi Shah:
About Home Chef, Jumpstart Ventures, Outcome Health, Pritzker Group Venture Capital: Outcome Health delivers better health outcomes and impacts the human condition positively through technology.
Daniel Burnett
Founder and Chairman of Bone Health Technologies
Dr. Burnett has a long history of biomedical device design and testing. After graduating from University of Pennsylvania’s school of Bioengineering, Dr. Burnett spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the- art devices. Following receipt of his MD and MBA degrees from Duke University, Dr. Burnett completed his one-year internship at the Mayo Clinic in Jacksonville, FL and is currently a licensed physician in the state of California. After working for two years as a General Partner with MedVenture Associates, a medical device venture capital firm in Emeryville, CA, Dr. Burnett left the firm in 2006 and committed himself to TheraNova and its subsidiaries.
Follow Daniel Burnett:
About Ananya Health, Anathem Ventures, Bone Health Technologies, Channel Medsystems, Consano, Gravitas Medical, Perikinetics, Potrero Medical, Respirix, TheraNova LLC., University of California, San Francisco: Bone Health Technologies is developing a new standard of care for treating both osteoporosis and osteopenia, the precursor to osteoporosis.
Alex Gorsky
Chairman & CEO of Johnson & Johnson
Follow Alex Gorsky:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Karen Licitra
Group Chairman of Johnson & Johnson
Karen A. Licitra served as Corporate Vice President at Johnson & Johnson. Ms. Licitra led Worldwide Government Affairs & Policy and was responsible for Johnson & Johnson’s engagements with global government leaders at the multilateral, national and state levels. Her organization also led development of Johnson & Johnson public policy. She served as Worldwide Chairman of the Global Medical Solutions Group within Johnson & Johnson’s Medical Device and Diagnostics segment. She was responsible for establishing the strategy and vision for an $8 billion global portfolio of healthcare companies including Vision Care, Diabetes Care, Ortho Clinical Diagnostics, and Advanced Sterilization Products as well as the Computer Assisted Personalized Sedation business unit. Ms. Licitra also served as Company Group Chairman and Worldwide Franchise Chairman of Ethicon Endo-Surgery, Inc., the Minimally Invasive Surgery division of Johnson & Johnson. She was named to Fortune’s 50 Most Powerful Women in Business list in 2012. She holds a Bachelor of Science Degree in Marketing from Rider University (Formerly, Rider College).
Follow Karen Licitra:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Bruce Booth
Chairman of the Board of Kymera Therapeutics
Bruce is a Co-Founder and the Chairman of the Board at Kymera Therapeutics. He’s also a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been instrumental in forming unique, innovative, and capital-efficient structures for drug discovery and development. He is a co-founder/founding investor and currently chair of the board of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. Along with Peter Barrett, Bruce seeded, incubated, and serves on the board of Zafgen (NASDAQ: ZFGN), and Bruce is a board member of Lysosomal Therapeutics Inc. (LTI) and Unum Therapeutics. Previously, he served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others. Previously, Bruce was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s private equity activities, ranging from early-stage venture capital through late-stage buyouts. Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Bruce currently serves as a trustee of the New York Academy of Medicine and is a term member of the council on foreign relations. He received a DPhil from Oxford University as a Marshall Scholar and a BS from the Pennsylvania State University.
Follow Bruce Booth:
About Atlas Venture, Nimbus Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Farhad Khosravi
Chairman & CEO of Imperative Care
Farhad Khosravi is the Executive Chairman and Co-Founder at Tulavi Therapeutics.
Follow Farhad Khosravi:
About Access Closure, Embolic Protection, Hotspur Technologies, Imperative Care, Imperative Care, Incept, Instylla, Ocular Therapeutix, Ostial Corporation, Tulavi Therapeutics, Tulavi Therapeutics: Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.
Joshua Boger
Executive Chairman of Alkeus Pharmaceuticals
Dr. Joshua Boger is the founder and former CEO of Vertex Pharmaceuticals Incorporated. He served in the additional role of Chairman of the Board from 1997 until 2006, and currently serves as a Board Member. Dr. Boger served as Vertex’s Chief Scientific Officer from 1989 until 1992 and has been a Director since Vertex’s inception. Dr. Boger served as Chairman of Bio, the Biotechnology Industry Organization, from 2007-2009. Dr. Boger holds a B.A. in chemistry and in philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry.
Follow Joshua Boger:
About Alkeus Pharmaceuticals: Alkeus Pharmaceuticals Inc., a Boston-based startup focused on treatments for serious ophthalmic conditions.
Pratik Shah
Executive Chairman & Co-Founder of Design Therapeutics
Pratik Shah is the Co-Founder and Executive Chairman of Design Therapeutics.
Follow Pratik Shah:
About CNS Therapeutics (Old), Design Therapeutics: Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Etienne Deffarges
Vice-Chairman of R1 RCM
Etienne Deffarges is an entrepreneur and part of the founding team — EVP and vice chairman of Accretive Health (now R1 RCM), a healthcare IT start-up that had its own IPO in 2010. He also holds a variety of board positions in aerospace, automotive, construction, food, energy, and healthcare. Etienne holds an MBA from the Harvard Business School, graduating as a Baker Scholar.
Follow Etienne Deffarges:
About : R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models.
Miles White
Executive Chairman of the Board of Abbott
Follow Miles White:
About Abbott, Abbott, The American Academy of Arts & Sciences: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
John Sculley
Chairman and CMO, Investor of RxAdvance
John Sculley joined RxAdvance Corp as Chairman and CMO, Investor in 2015. John Sculley is a partner in Sculley Advisors LLC, a private family office founded by John Sculley and his wife, Diane Sculley. John Sculley was Chief Executive Officer of Apple Computer. John Sculley joined Apple in 1983 when the Company had $600 million in revenues; by the time he left, Apple’s revenues exceeded $8 billion. Prior to joining Apple, Sculley was CEO of Pepsi from 1973 to 1983.
Follow John Sculley:
About Misfit Wearables, RxAdvance, RxAdvance, Sculley Brothers, The Real McCoy: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
David Silbersweig
Chairman, Dept of Psychiatry; Co-Director, Center for the Neurosciences of Brigham and Women’s Hospital
David Silbersweig, MD, is one of the pioneers of functional neuroimaging research in psychiatry. The aim of his current work in systems-level neuropathophysiology is to help provide a foundation for the development of novel, targeted, and biologically based diagnostic and therapeutic strategies to aid those suffering with mental illness. Dr. Silbersweig is now the Chairman of the Department of Psychiatry at the Brigham and Women’s/Faulkner Hospitals, and Chairman of the Brigham and Women’s Hospital Institute for the Neurosciences. He also is Stanley Cobb Professor of Psychiatry at Harvard Medical School.
Follow David Silbersweig:
About Brigham and Women’s Hospital: Brigham and Women’s Hospital is an academic medical center based in Boston, Massachusetts.
Cameron Teitelman
Founder, Chairman, and head of admissions and oversee investment vehicles of StartX (Stanford-StartX Fund)
Cameron Teitelman is the Founder and Chairman of StartX, a 501 (c)(3) nonprofit that runs an accelerator for Stanford affiliated entrepreneurs. Under his management, StartX has supported more than 1,100+ founders building 500+ companies. StartX companies have raised over $3.3B to date. In 2013, the Stanford-StartX Fund was launched. To date, SSF has invested in 250 StartX companies across 400+ rounds, investing $130 million in capital.
Follow Cameron Teitelman:
About StartX (Stanford-StartX Fund): StartX is an educational non-profit that helps Stanford’s top entrepreneurs.
William C. Wortman
Director and Chairman of Exact Imaging
Mr. Wortman has been a director of Imagistx since April 2009. Mr. Wortman is presently a co-owner of Millennium Gaming. Inc. (MGI). MGI is the majority owner of Cannery Casino Resorts which owns and operates the Rampart Casino, Cannery Casino & Hotel and Eastside Cannery Casino & Hotel in Las Vegas and the Meadows Racetrack & Casino in Pennsylvania. Mr. Wortman began his career as an accountant with Laventhol & Horwath in 1974. In 1978 he joined Caesars Palace as financial controller and during the next six years, held various executive positions and though his efforts helped establish the Caesars brand as an industry leader. In 1983, Mr. Wortman purchased the Fallon Nugget and the Bonanza Inn and operated them until he sold them in 1996. In 1985, he purchased a substantial equity position in Nevada Palace in Las Vegas, a facility that was involved in a bankruptcy proceeding. Mr. Wortman, as managing partner assumed operating control restoring the facility to profitability. In 2006, Nevada Palace was sold to Cannery Casino Resorts. In addition to Imagistx, Mr. Wortman currently serves as a member of the UNLV Foundation Board of Trustees, board member of the UNLV Graduate School of Business, Board of Directors for Meadows Bank and the UNLV Leadership Campaign Committee. Mr. Wortman was the 1986 recipient of the Alumni of the Year Award for UNLV. Mr. Wortman received his Bachelor of Science in Accounting from UNLV.
Follow William C. Wortman:
About Cannery Casino Resorts LLC, Exact Imaging, Millennium Gaming. Inc: Exact Imaging is the developer of the ExactVu™ system, the first micro-ultrasound operating at 29 MHz that provides unmatched resolution.
Vicki Sato
Chairman of Vir Biotechnology
Vicki L. Sato, Ph.D., serves as chairman of the board of directors at Vir. Dr. Sato is also a professor of management practice at Harvard Business School, and an affiliate member of the Department of Molecular and Cell Biology, Harvard University. She has taught in HBS Executive Education programs and is a business advisor to enterprises in the biotechnology and pharmaceutical industries. Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as president since 2000, with responsibility for research and development, business and corporate development, commercial operations, legal, and finance. Prior to becoming president, she was chief scientific officer, senior vice president of research and development, and chair of the Scientific Advisory Board. Under her leadership, Vertex created a diversified pipeline of drugs. Before joining Vertex, Dr. Sato was vice president of research at Biogen, Inc., where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and she participated in the executive management of the company. Several molecules from those programs have now reached the marketplace. She also served as a member of the Biogen Scientific Board. Currently, Dr. Sato is a member of the board of directors of publicly held companies Bristol Myers Squibb Company, PerkinElmer Corporation, Borg Warner Corporation, and Syros Pharmaceuticals. She also serves as chair of the board of directors for Denali. Previously, Dr. Sato has served as an overseer of the Isabella Stewart Gardner Museum. She received her A.B. from Radcliffe College, and her A.M. and Ph.D. degrees from Harvard University. Following postdoctoral work at both the University of California Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology.
Follow Vicki Sato:
About : Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Nitin Nanda
CEO,Founder & Chairman of Aligned TeleHealth
Dr. Nitin Nanda, founder of Aligned Telehealth, is a respected physician, entrepreneur, leader, and educator. Since founding the Company in 2000, Dr. Nanda has grown Aligned Telehealth into one of the largest behavioral health specialty practices in the US. He built a successful practice model based on clinical expertise, compassion, operational efficiency and fiscal responsibility. He is Assistant Clinical Professor at the UCLA David Geffen School of Medicine and Clinical Assistant Professor in Medicine at the USC Keck School of Medicine. Dr. Nanda is Chief of Psychiatry and Behavioral Health at the Los Angeles Jewish Home. He also serves as Medical Director of the Lisa and Ernest Auerbach Geriatric Psychiatry Unit at the Joyce Eisenberg-Keefer Medical Center in Los Angeles. Dr. Nanda obtained his medical training in India and served briefly in Africa, where he worked with community hospital and clinics, caring for the very ill and underserved. He then joined UCSF School of Medicine’s Clinical Research department. Later, Dr. Nanda completed an Internship and Residency at the UCLA David Geffen School of Medicine, where he was nominated Chief Resident. With a deep interest and passion in caring for seniors, Dr. Nanda pursued a Geriatric Psychiatry Fellowship at UCLA.
Follow Nitin Nanda:
About Aligned TeleHealth, Amwell: Aligned Telehealth is a provider of a SaaS-based platform used to offer telemedicine and healthcare management services.
Michael T. Heffernan
President , CEO & Chairman of the Board of Collegium Pharmaceutical
Michael Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain. He was also previously the founder, President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses and was responsible for the spin-off of this business to create PreCision Dermatology. Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold. He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company. Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in a number of healthcare companies. He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company and PreCision Dermatology. Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
Follow Michael T. Heffernan:
About AvengeBio, Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Alex Jimenez-Ness
Founder and Executive Chairman of Welwaze
Alex Jimenez-Ness is an entrepreneur with a strong passion for a humanistic approach to technology and science. Originally from Spain, Alex has dedicated over 20 years to build his career in private equity in the U.S., after starting his career in private banking in Europe.Alex founded Sofos Capital, a multifamily office wealth advisory group, Domus One Group, a private equity platform for real estate developments, and One Eleven Capital, a private equity firm managing capital across selected asset classes, which consequently led him to found and spearhead Welwaze Medical.The recession in 2008 brought a great deal of personal growth and Alex shifted his investment strategy focusing on companies and opportunities that have a strong social impact while creating value and return to his investors and shareholders.Alex is a early stage investor in technology startups and currently sits on the Board of three family groups. He is invited to speak to groups looking for inspiration, purpose, and growth.His continuous support to Miami’s community has earned him recognition as a Miami-Dade County Key recipient
Follow Alex Jimenez-Ness:
About Welwaze: Welwaze develop tools to empower people to manage their health, and improve the way they live.
Lixiao Wang
Founder, Chairman, and Board of Directors of Urotronic
Lixiao Wang is the Founder, Chairman, and Board of Directors of Urotronic, Inc.
Follow Lixiao Wang:
About Urotronic: A Minnesota based, medical device company, making an exciting innovation in urethral stricture treatment.
Maurice Ferre, M.D.
CEO & Chairman of InSightec
Dr. Maurice R. Ferré was the founding President and Chief Executive Officer of MAKO Surgical Corp, serving from 2004 until the acquisition of the company by Stryker Corp. for $1.7 billion in 2014. In June 2007, Dr. Ferré received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. In 1993, he founded Visualization Technology, Inc., a medical device company for image-guided surgery, where he served as Chief Executive Officer until 2002 when the company was acquired by GE Healthcare, the healthcare division of the General Electric Company. Dr. Ferré served as Vice President of Strategic Development for GE Navigation, a Division of GE Healthcare, until 2004. Dr. Ferré holds an M.D. and a Master’s degree in Public Health from Boston University.
Follow Maurice Ferre, M.D.:
About DermaSensor, InSightec: InSightec develops and manufactures MR-guided Focused Ultrasound technology devices for image-guided acoustic surgery.
Brent Shafer
Chairman & CEO of Cerner
As chairman of the board of directors and chief executive officer of Cerner, Brent Shafer focuses on growing and expanding Cerner’s market-oriented business units, consumer brand, key strategic relationships and priority corporate initiatives. Previously chief executive officer of Philips North America, Shafer oversaw a health technology portfolio that included a broad range of solutions and services covering patient monitoring, imaging, clinical informatics, sleep and respiratory care as well as a group of market-leading consumer-oriented brands. Shafer also was previously the chief executive officer of the global Philips Home Healthcare Solutions business. Shafer has extensive experience driving value-based business models from a foundation of innovation. He has helped lead the growth of a complex multinational organization over a number of years in senior leadership positions with Philips. He has also served in senior leadership positions at other companies, including GE Medical Systems, Hill-Rom and Hewlett-Packard. Shafer started his career at Intermountain Healthcare’s Primary Children’s Hospital. He serves on the board of No Barriers USA, a nonprofit that organizes life-changing experiences for youth, veterans and people with disabilities. Shafer is also active in the Health Management Academy, a community of executives from the largest U.S. integrated health systems and most innovative health care companies. He has a bachelor’s degree from the University of Utah.
Follow Brent Shafer:
About Cerner, Philips: Cerner is a supplier of healthcare information technology solutions, services, devices, and hardware.
Peter Soderberg
Chairman Of The Board and Investor of ABM Respiratory Care
Chairman Of The Board and Investor at ABM Respiratory Care.
Follow Peter Soderberg:
About ABM Respiratory Care, Tactile Medical, Worthy Venture Resources, LLC: ABM Respiratory Care is a medical device startup that develops ventilation solutions for people suffering from pulmonary diseases.
Eric Xing
Founder, Executive Chairman, Chief Scientist of Petuum
Eric Xing is a professor at Carnegie Mellon University and researcher in machine learning, computational biology, and statistical methodology.
Follow Eric Xing:
About Carnegie Mellon University, Petuum: Petuum, Inc. is building a platform that serves the full spectrum of Artificial Intelligence
Tim Koogle
Investor, Board member, and Chairman of Cadence Health Inc
Tim Koogle joined Cadence Health as Investor, Board member, and Chairman in 2017.
Follow Tim Koogle:
About Cadence Health Inc, ecover, eCoverage, Olly Ltd, Serendipity Land Holdings, LLC, The Koogle Foundation, True Botanicals: Cadence Health is a consulting company bringing Industrial and System Engineering tools to complex health systems.
Dean Travers
Co-Founder & Chairman of Luminopia
Dean Travers is the Co-Founder & CEO at Odin.
Follow Dean Travers:
About Luminopia, Odin: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Marshal Linder
Chairman, CEO of Breethe
Marshal Linder is the Chairman and CEO of Breethe, Inc.
Follow Marshal Linder:
About Breethe: Breethe is a medical device company that develops a compact artificial lung for patients with acute and chronic lung problems.
Matthew Emmens
Chairman of the Board of Director of Vertex Pharmaceuticals
Matthew was appointed Chairman on June 18, 2008 and has been a member of the Board since March 12, 2003.He is also a member of the Nomination Committee. He was the Company’s Chief Executive Officer from March 2003 to June 2008.Matthew brings to the Board his operational knowledge of Shire and his wealth of international sales, marketing, integration and operational experience in the pharmaceutical sector. Matthew is a Director of Vertex Pharmaceuticals Inc.He served as Chairman, CEO and President of Vertex Pharmaceuticals Inc. from 2009 until early 2012 and is a former Director of Incyte Corporation.
Follow Matthew Emmens:
About : Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Guy Miller
Chairman, CEO & Co-Founder of Edison Pharmaceuticals
Guy Miller, MD, PhD is the co-founder of Edison Pharmaceuticals, and has served as Chairman and Chief Executive Officer of the Board since 2005. Prior to founding Edison, he founded Galileo Pharmaceuticals, a biopharmaceutical company, and was its Chairman and CEO from 1995-2005. Dr. Miller holds an MD from the Medical College of Pennsylvania and a PhD in chemistry from the University of Virginia. He completed his surgical internship at the University of Chicago, and a residency in anesthesiology and critical care medicine at Johns Hopkins. Dr. Miller completed a fellowship in multidisciplinary critical care medicine at Johns Hopkins, where he was on the faculty as an Assistant Professor until 1996. He is currently an attending physician in medical-surgical critical care medicine at Stanford University-PAVAMC.
Follow Guy Miller:
About Ampere Life Sciences, BioElectron Technology Corporation, Edison Pharmaceuticals, Stanford University School of Medicine: Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Aaron Greenblatt
Chairman of Flipt RX
Years in Pharmaceutical Industry: 4 Areas of Specialty & Work History: Aaron completed his undergraduate studies at University of Maryland College Park, and received his PharmD from University of Maryland School of Pharmacy. Aaron rotated through several departments in G&W during various summer internships throughout high school and college. Aaron formally joined G&W full-time in 2009 as the head of Supply Chain. After building the newly formed Supply Chain department at G&W, Aaron also ran the packaging department before moving into his role as Director of Sales, Business development, and company culture. Aaron currently focuses on developing new growth opportunities for G&W while deepening customer relationships, and ensuring that G&W attracts and retains employees that are aligned with its core values. Aaron is passionate about entrepreneurship, company culture and core values, leadership, personal growth, team building, impact, and building new relationships. Areas of interests include; Supply Chain, Efficiency, Customer relationships, Organizational Development, Business Strategy and Development, and building a culture of sustainable growth. Aaron has taken the opportunity to direct these passions towards the growth and continuous evolution of G&W Laboratories. Hobbies and Family: Aaron enjoys reading (especially at the beach), going to concerts, windsurfing, golf, traveling and playing basketball. He is also a food and wine enthusiast, a loyal fan of the NY Yankees, the NY Giants, and recently got engaged.
Follow Aaron Greenblatt:
About Flipt RX, G&W Laboratories: Flipt RX manages pharmacy benefits.
J. Kurt Jacobus
Chairman and CEO of Restor3d
Kurt Jacobus is a Managing Director of the GRA Venture Fund.
Follow J. Kurt Jacobus:
About Restor3d: Restor3d offers surgeons with biomaterials, 3D printing technologies, and artificial intelligence to repair and rebuild the human body.
John Mazziotta
Chairman, Department of Neurology of UCLA Health System
Follow John Mazziotta:
About UCLA Health System: UCLA Health has provided the best in healthcare and the latest in medical technology to the people of Los Angeles and throughout the world.
Ron Zwanziger
Co-Founder, Chief Executive Officer, Chairman, and Director of LumiraDx
Ron Zwanziger, a strategic visionary and entrepreneur, is the CEO of LumiraDx, which he co-founded in 2014. He previously founded and led numerous successful diagnostic firms, including Alere, Inverness Medical Technology (which was acquired by Johnson & Johnson in 2001), and MediSense, the first company to introduce an electrochemical glucose sector. He currently serves on the Board of Directors of several private companies.
Follow Ron Zwanziger:
About LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Martin Rash
Chairman of the Board of Directors of RCCH HealthCare Partners
Martin Rash is Executive Chairman of RCCH Healthcare Partners. Prior to the forming of RCCH, Martin was Chairman and CEO of RegionalCare Hospital Partners. Martin has also served as Chairman and CEO of Province Healthcare, a $1 billion NYSE company that owned 21 hospitals and managed more than 50 facilities. Prior to his tenure at Province Healthcare, Martin served as Executive Vice President and Chief Operating Officer for Community Health Systems where he led the growth of the company from 10 to 41 hospitals in 17 states. Earlier in his 25-year healthcare career, Martin worked at numerous community hospitals in various executive, administrative, and financial roles. Martin’s experience and leadership includes membership on the development team of the largest hospice company in the country and a long-term board seat on the largest Medicare Advantage program in the United States. Martin is a past chairman and one of the co-founders of the Federation of American Hospitals and has also previously served as Chairman of the Nashville Healthcare Council. Martin Rash holds both a bachelor’s and MBA from Middle Tennessee State University.
Follow Martin Rash:
About RCCH HealthCare Partners: RCCH HealthCare Partners provides healthcare services.
Chintu Patel
Co-Chief Executive Officer and Co-Chairman & Co-Founder of Amneal Pharmaceuticals
Chintu’s vision of building an innovative pharmaceutical company based upon quality and integrity has guided every chapter of the Amneal story. Formerly a pharmacist, he has over 20 years of distinguished experience within the industry and has been recognized by his peers on numerous occasions including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. He is an ardent philanthropist dedicated to supporting both business and non-profit organizations including a variety of charitable foundations and holds a bachelor’s degree from Rutgers College of Pharmacy.
Follow Chintu Patel:
About Amneal Pharmaceuticals: Amneal Pharmaceuticals manufactures, markets and/or distributes more than 88 drugs in the United States.
Eirini Schlosser
Chairman & CEO of Dyania Health
Follow Eirini Schlosser:
About Dyania Health, MedicusData.AI: Dyania Health develops a research platform for pharma companies and hospital systems.
Rocco Ortenzio
Vice Chairman and Co-Founder of Select Medical
Rocco A. Ortenzio, a co-founder of the Company and a member of its Board of Directors since February 2005, has served as the Company’s Vice Chairman and Co-Founder since January 2014. He served as the Company’s Executive Chairman since February 2005. In 1997, Mr. Ortenzio co-founded and served as a member of the Board of Directors of the Company’s subsidiary, Select Medical Corporation (“SMC”). He served as the Executive Chairman of SMC from September 2001 to February 2005, and as its Chairman and Chief Executive Officer from February 1997 to September 2001. In 1986, he co-founded Continental Medical Systems, Inc., a provider of comprehensive medical rehabilitation services, and served as its Chairman and Chief Executive Officer until July 1995, when it merged with Horizon Healthcare Corporation. In 1979, Mr. Ortenzio founded Rehab Hospital Services Corporation, a hospital chain acquired by National Medical Enterprises, Inc. (now called Tenet Healthcare Corporation) in January 1985, and served as its Chairman and Chief Executive Officer until June 1986. In 1969, Mr. Ortenzio founded Rehab Corporation and served as its Chairman and Chief Executive Officer until 1974, when it merged with American Sterilizer Company. From 1996 to 1999, he served on the Board of Governors of the Pennsylvania State System of Higher Education. Mr. Ortenzio serves as a Director of Quorum Health Group, Inc., and is a fund advisor to HLM Partners Inc., a venture capital firm located in Boston, Massachusetts, and Dauphin Capital Partners, a venture capital fund located in Locust Valley, New York.
Follow Rocco Ortenzio:
About Select Medical: Select Medical treats approximately 30,000 patients in a typical day.
Larry Papasan
Chairman of the Board of Directors of MEDOVEX
Larry Papasan is the retired President of Smith & Nephew Orthopedics. Larry joined Smith & Nephew in July, 1991 as President of the Ortho Division and retired December 31, 2002. During this 11-1/2 year period, the Division grew in sales from $300 million to $650 million while growing profitability at over 15% per year. Smith & Nephew Orthopedics is a company with manufacturing in Memphis and Germany. Larry was responsible for Research and Development, Manufacturing, Marketing, Sales and all Administrative functions of the Company during his 11-1/2 year tenure as President. Larry then worked for Smith & Nephew as a Director and Lobbyist until the end of 2005. Prior to joining Smith & Nephew, Larry was President of Memphis Light, Gas & Water Division from 1984 until his retirement in 1991. Larry was employed by MLG&W for 28 years. Larry has been a Member of the Board of Directors and Chairman of the Board of Directors of BioMimetic Therapeutics [NasdaqGM:BMTI] since August 2005. BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. Larry has also served as a Member of the Board of Directors at Reaves Utility Income Fund [NasdaqCM:UTG], a closed-end management investment company, since February 2003, SSR Engineering, Inc. and AxioMed Spine Corporation. Larry graduated from Mississippi State University in 1963 with a Bachelor of Science in Civil Engineering. Larry has completed numerous professional development courses, including the American Management Association Management course, Senior Management course and President’s course. Larry has been very active in the Memphis Community and was General Campaign Chairman of United Way in 1987 and Chairman of the Board from 1990-92, President of Kiwanis Club and President of Junior Achievement. Currently, he is involved with several organizations, some of which are BioMimetic Therapeutics, Inc., BioMedical Tissue Technologies, Ltd. and the Shelby Farms Park Conservancy. Larry is married and has two grown children and five grandchildren. He is an avid golfer.
Follow Larry Papasan:
About MB Venture Partners: MEDOVEX’s management team and board of directors are highly experienced healthcare professionals in all functional areas
Patrick Spain
Co-Founder, Chairman & CEO of First Stop Health
Patrick Spain started First Stop Health because of his own unsatisfactory experience with the healthcare system and his desire to improve that experience for others. Spain is a serial entrepreneur who has founded or cofounded four Web-based companies. Co-founder and long-time chairman and CEO of Hoover’s, Inc., Spain led the company from a small book publisher in 1992 to a profitable, publicly traded online business information services company with $31 million in revenue in 2001 with a sale to D&B in 2003 for $119 million. Spain was also the founder, chairman and CEO of HighBeam Research, which he started in 2002 and sold to Cengage Learning in December, 2008. He also co-founded and serves as executive chairman of Newser, a news filtering and summarization service with an audience of over three million readers each month. Spain serves as a board member of Televerde a rapidly growing, socially responsible telemarketing service and InfoArmy a Silicon Valley-based company information service that is using crowd sourcing to revolutionize data collection, quality and delivery. Until recently Spain served on the boards of SmartAnalyst, a research company that serves the pharma industry and GuideStar, the largest and most trusted database of information on the not-for-profit sector. Spain is a member of the Board of Governors of Opportunity International, the largest and best capitalized micro-lender in the world. Spain has worked in the technology industry since 1979 and has a bachelor’s degree from the University of Chicago and a law degree from Boston University. He lives in the Chicago area with his wife and three daughters.
Follow Patrick Spain:
About First Stop Health, Newser, Occasion: We provide care that people love with 24/7 access to licensed doctors via app, web or phone.
Josef Parvizi
Chairman, Founder of Ceribell
Follow Josef Parvizi:
About Ceribell, Stanford University: Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.
Timothy Walbert
Chairman, President & Chief Executive Officer of Horizon Pharma
Mr. Walbert has served as chairman of our board of directors since 2010 and our president and chief executive officer since June 2008. Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which is on track to exceed $10.0 billion in 2013 sales, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College, in Allentown, Pennsylvania. Mr. Walbert serves on the board of directors of XOMA Ltd. (NASDAQ: XOMA), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. Mr. Walbert was also recently appointed by Illinois Governor Pat Quinn to the Illinois Innovation Council.
Follow Timothy Walbert:
About Horizon Pharma, Horizon Therapeutics, Viela Bio: Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Paul Edalat
Chairman of the Board, Interim CEO, CBDO of Vivera Pharamceuticals
With more than 30 years of brand and product development experience in the nutraceutical, pharmaceutical, and medical device sectors, Mr. Edalat brings a keen eye for business development and growth opportunities to Vivera. His forward-thinking management approach as interim CEO has seen Vivera grow from a single division at its founding to over seven divisions and counting today. Leading Vivera’s business development domestically and internationally, Mr. Edalat works closely with Vivera’s sales and marketing teams to anticipate and meet market demands. With trusted global relationships built over the decades, Mr. Edalat has worked to leverage his connections and expand Vivera’s reach. At home, he has led the Company through innovative research and development, focusing on maintaining Vivera’s core mission – putting patients first. www.pauledalat.com
Follow Paul Edalat:
About Vivera Pharamceuticals: Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California.
Itai Danovitch
Chairman, Department of Psychiatry and Behavioral Neurosciences of Cedars Sinai Medical Center
Follow Itai Danovitch:
About Cedars Sinai Medical Center, Cedars Sinai Medical Center, Mental Health Services Oversight & Accountability Commission: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Michael Alexander
Professor and Vice-Chairman of Cedars Sinai Medical Center
Michael Alexander is Board of Directors at Cedars-Sinai.
Follow Michael Alexander:
About Cedars Sinai Medical Center: Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California.
Christopher SD Lee
Chairman & CEO, Co-Founder of Huxley Medical
Christopher SD Lee is the Founder and CEO at Huxley Medical. He also works as a mentor at Creative Destruction Lab.
Follow Christopher SD Lee:
About Creative Destruction Lab (CDL), Huxley Medical: Huxley Medical was founded by serial entrepreneurs to bring clinical-grade care to any person anywhere.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Thomas D. Weldon
Co-Founder, Chairman, and Managing Director of Accuitive Medical Ventures
Tom Weldon is the Founder, Chairman & CEO at Ponce De Leon Health.
Follow Thomas D. Weldon:
About Accuitive Medical Ventures, Innovation Factory, Ponce De Leon Pharmaceuticals, The Innovation Factory: Accuitive Medical Ventures is a Georgia-based venture capital firm that invests in early-stage medical device and technology companies.
Dan Barnes
Executive Chairman & Co-Founder of FamilyWize
Dan has led FamilyWize since 2005 when he and his wife Susan founded the FamilyWize Community Service Partnership. Dan’s vision for FamilyWize stems from his 25 years’ experience and expertise in large wholesale, consumer group buying and membership benefits. Under his leadership, the FamilyWize prescription assistance program has helped millions of people save more than $1 billion on the cost of their medicine. Dan and Susan and their two boys live in Lehigh Valley, Pennsylvania.
Follow Dan Barnes:
About FamilyWize: FamilyWize has been dedicated to helping improve the health and well-being of individuals, families.
Dustin Shindo
Chairman and CEO of Pono Pharma
Dustin serves as the Chairman of the Board of Directors of Kai Medical. Dustin founded Hoku Corporation and served as its Chairman of the Board, President, and CEO from March 2001 to March 2010. While serving as Chairman of the Board, President, and CEO at Hoku, Dustin led the company to a successfully IPO on the NASDAQ Global Market. He also partnered with global customers including Sanyo, Nissan, Suntech Power, the US Navy, Solarfun, and others, with contracts totaling $2 Billion. Dustin has previously overseen successful ventures in both the software and manufacturing industries. Dustin has a B.A. in Accounting from the University of Washington and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
Follow Dustin Shindo:
About Kai Medical, Pono Pharma: Pono Pharma develops and commercializes therapies for certain cancers and other diseases.
Gregory C. Critchfield
Chairman, President and CEO of Sera Prognostics
Dr. Gregory Critchfield is CEO of Sera Prognostics, a private biotechnology company developing novel diagnostic tests for the early prediction of preterm birth and other pregnancy complications. He currently serves as an independent director of Saladax Biomedical, Metamark Genetics and Nodality. Dr. Critchfield is also past President of Myriad Genetic Laboratories, Inc., where he successfully established the company’s medical, scientific, and commercial capabilities beginning in 1998 until he retired in March 2010. During this time, Dr. Critchfield built Myriad Genetic Laboratories into one of the world’s leading molecular diagnostics companies, launching seven novel diagnostics products across multiple technology platforms and growing annual revenues from $2.2 million to $326.5 million. In the spin-out of Quest Diagnostics, Inc. from Corning Clinical Laboratories, Dr. Critchfield was responsible for innovation and medicine, serving as Quest’s Chief Medical and Science Officer. From 2007 to 2009, Dr. Critchfield served as an independent Director of BioTrove, a venture-backed molecular biological tools company. In that position he collaborated with Albert A. Luderer, Ph.D., CEO of Indi, who was then BioTrove’s CEO. They worked together at BioTrove until that company was successfully acquired by Life Technologies in December 2009. In 2007, Dr. Critchfield chaired the Utah Governor’s State Advisory Council on Science and Technology. He served on the Board of the American Clinical Laboratory Association (ACLA). Earlier in his career Dr. Critchfield worked as a practicing clinical pathologist with Intermountain Healthcare for nine years. Previously, he served as a reviewer and study section chair for the NIH for more than 15 years, working in biomedical computing programs for SBIR, STTR and R01 programs. Dr. Critchfield’s research has focused on building quantitative models in many areas of laboratory medicine including anticoagulation control, method standardization, mass spectrometric identification of drugs, predictive value modeling, quantitative health policy analysis and clinical genetics. He has served on the faculty of three medical schools: University of Minnesota, Wayne State University and Duke University. Dr. Critchfield received a Bachelor’s Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an M.D. from the University of Utah in 1980, and a master’s degree in Biophysical Sciences at the University of Minnesota in 1985. He also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and is board certified in Clinical Pathology.
Follow Gregory C. Critchfield:
About Duke University, Epic Sciences, Sera Prognostics, Wayne State University: Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.
Mitchel Berger
Professor and Chairman, Department of Neurological Surgery of UCSF health
Dr. Berger’s main clinical interests are the treatment of brain tumors in adults and children and of epilepsy related to brain tumors. He has extensive expertise in intraoperative mapping of the brain to identify the sites of motor, sensory, and language function and thereby avoid their involvement or injury during surgery. Dr. Berger is Director of the Adult Hydrocephalus and Shunt Program, and he also practices in the Neuro-Oncology Program and the Radiosurgery Program.
Follow Mitchel Berger:
About UCSF health: UCSF health offers healthcare services in the areas of cancer, heart disorders, neurological disorders, organ transplants, and more.
Parker H. Petit
Chairman of MiMedx Group
Pete Petit joined MiMedx® Group, Inc. in February 2009 as the Company’s Chairman and Chief Executive Officer. A visionary healthcare executive, he has a history of developing companies from their emerging stages and leading them to maturity and significant stature in their respective markets. In 1970, Mr. Petit founded Healthdyne, an international healthcare company that manufactured high technology healthcare devices, provided healthcare information systems and technology, and provided healthcare services and disease management. The Healthdyne related companies grew to annual revenues in excess of $1 billion. In order to increase shareholder values, Healthdyne was split into several publicly traded companies through public offerings and spinouts to shareholders in 1995. At that point, he relinquished the CEO role and remained Chairman of the Board of all the companies. Subsequently, the home infusion therapy subsidiary was sold to W. R. Grace Corporation. In 1995, Healthdyne Maternity Management was merged with Tokos Medical to form Matria Healthcare. In 1997, Healthdyne Technologies was merged with Respironics. He resumed the duties of President and CEO of Matria Healthcare in 2000. In 2001, Healthcare.com, which was formerly Healthdyne Information Enterprises, merged with XCare.net Corporation to form Quovadx. Through his vision and leadership, Matria Healthcare transitioned into the industry’s only fully integrated health, productivity and disease management care continuum providing employer and health plan clients access to wellness programs, nurse triage services, decision support programs, disease management programs for chronic diseases, case management programs for acute and catastrophic conditions and unparalleled health data integration and informatics. Matria Healthcare was sold to Inverness Medical Innovations in May of 2008 in a transaction valued at over $1.2 billion. Pete Petit served on the Board of Directors of Atlantic Southeast Airlines for 16 years until it was acquired by Delta Airlines, and Norrell Corporation, which was acquired by Spherion Corporation. He currently serves on the Board of Trustees of the National Health Museum and is a member of the Board of Directors of Intelligent Systems Corporation. He is a member of the Board of Directors of the Georgia Research Alliance, which is chartered by the state of Georgia to promote high technology and scientific development in the state, and he is a 1994 inductee into the Technology Hall of Fame of Georgia. Mr. Petit received his Bachelor’s degree in Mechanical Engineering and Master of Science degree in Engineering Mechanics from Georgia Tech. He received his MBA degree in Finance from Georgia State University in 1973.
Follow Parker H. Petit:
About MiMedx Group: MiMedx Group provides regenerative biologics utilizing human placental tissue allografts with patent-protected processes.
Gary Stroy
Chairman of Xip
Follow Gary Stroy:
About Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
David Hysong
Founder, Patient & Chairman of SHEPHERD Therapeutics
SHEPHERD is a biotechnology company that develops novel therapeutic candidates for a portfolio of rare cancers. SHEPHERD is also a development partner to other biopharma companies looking to develop their assets in rare cancers. Via SHEPHERD’s in-house capabilities and A.I. platform, DELVE, SHEPHERD can help match any drug with the rare cancers in which it will be most effective.
Follow David Hysong:
About Forbes, SHEPHERD Therapeutics, SHEPHERD Therapeutics, The Aspen Institute: SHEPHERD Therapeutics specializes in finding cure to rare cancers.
Mike Doodson
Executive Chairman and Co-founder of G2B Pharma
Follow Mike Doodson:
About G2B Pharma: G2B Pharma is a biotechnology company focused on the reformulation of off-patent drugs.
Vin Ryan
Founder and Chairman of Schooner Capital
Vin is Founder and Chairman of Schooner, a firm which he started in 1971 and has managed for four decades. He serves as a Director of Iron Mountain, a $5 billion global records management company which he purchased and grew from a single storage site; a former Director of Continental Cablevision, where he invested and served on the board for more than two decades until the company was sold in 1996; and a founder of both National Hydro and Arch Mobile Communications. In addition, he has served on numerous boards of Schooner investments over the decades. In 1996, Vin created The Schooner Foundation, which supports a number of not-for-profit causes globally, with a particular emphasis on human rights. Vin served as a director of the Marine Biological Laboratory, the Isabella Stewart Gardner Museum, Physicians for Human Rights, and Survivor Corps (formerly Landmine Survivors Network). He also chairs the Advisory Board of the Carr Center at Harvard University’s Kennedy School of Government. Vin is a graduate of Boston University.
Follow Vin Ryan:
About Schooner Capital: Schooner Capital is a Boston-based private investment firm engaged in venture capital, growth equity, and public securities.
Daniel Zurr
CEO, Founder and Chairman of the Board of Quark Pharmaceuticals
Daniel Zurr Ph.D., CEO, Founder and Director, former President of Plantex Ikapharm (currently part of the Teva Group). Dr. Daniel Zurr founded Quark in 1993 and is currently CEO of the Company. Dr. Zurr also currently serves as a Director of QBI. Dr. Zurr has vast experience in senior research and business management in the chemical and pharmaceutical industries. Prior to establishing QBI, Dr. Zurr was the CEO of Plantex-Ikapharm, then the second largest pharmaceutical company in Israel with more than 300 employees and marketing offices in the United States, Europe and Japan, focused in the field of bulk active ingredients and finished dosage pharmaceuticals. During Dr. Zurr’s tenure, Plantex Ikapharm, now part of the Teva group of companies, became the first Israeli company ever to be inspected and approved by the FDA. In the early eighties, Dr. Zurr served as the Director of Licensing at G.D. Searle in Skokie, Illinois, where he was responsible for the major collaborative agreement between G.D. Searle and Meiji Seika Kaisha (Tokyo), involving the licensing of several drugs and recombinant DNA technology transfer. Dr. Zurr was also responsible for numerous other agreements, including those with Bayer AG (Leverkusen), Ono Pharmaceutical (Osaka) and May and Baker (London).
Follow Daniel Zurr:
About Kunshan RiboQuark Pharmaceutical Technology, Quark Pharmaceuticals: Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics.
Vicente Sáez González
Vice Chairman of Ixaka
Vicente is an experienced healthcare investor with over 20-years’ experience in numerous companies in Spain and in other European countries. These include Vidia Health, S.A., Group Axys Biosciences S.A, Estadista, S.A. and Iris Development S.A. Vicente is a co-founder and principal shareholder of Rexgenero and has significant experience of companies with partnerships with the public sector in Spain.
Follow Vicente Sáez González:
About : Ixaka is a private cell and gene therapy company with a focus on the natural power of the body to cure disease.
Timothy M. Ring
Chairman & Chief Executive Officer of C. R. Bard
Mr. Ring has been the Chairman and Chief Executive Officer of C. R. Bard, Inc. since 2003. He is a director of C. R. Bard, Inc. and was director of CIT Group Inc. from 2005 to 2009. Mr. Ring is a Trustee of the New Jersey Health Foundation. He has been a director of Quest Diagnostics since December 2011. Mr. Ring has extensive executive experience, including in strategic planning and international operations, with multinational corporations operating in the healthcare industry.
Follow Timothy M. Ring:
About C. R. Bard: C. R. Bard is a developer, manufacturer, and marketer of medical technologies.
John Weiland
Vice Chairman, President and Chief Operating Officer of C. R. Bard
John H. Weiland joined C. R. Bard, Inc. on March 1, 1996. His experience spans over 30 years in the healthcare industry with firms such as Dentsply International, Pharmacia and Baxter Healthcare Corporation. John was elected to the Board of Directors in April 2005 and assumed the title of Vice Chairman in August 2016.
Follow John Weiland:
About C. R. Bard: C. R. Bard is a developer, manufacturer, and marketer of medical technologies.
Robert Bailey
Chairman of Blue Willow Systems
Robert L. Bailey was the Chairman of the Board of Directors of PMC-Sierra (“PMC”) from 2005 until May 2011 and also served as PMC’s Chairman from February 2000 until February 2003. Mr. Bailey has served as a director of PMC since October 1996. He also served as the President and Chief Executive Officer of PMC from July 1997 until May 2008. PMC is a leading provider of broadband communication and semiconductor storage solutions for the next-generation Internet. Mr. Bailey currently serves on the Board of Directors of Entropic Communications. Mr. Bailey holds a BS degree in Electrical Engineering from the University of Bridgeport and an MBA from the University of Dallas. He has served on our Board of Directors since 2007.
Follow Robert Bailey:
About : Blue Willow Systems, a developer of a next-generation, cloud-based senior living community resident safety platform.
Manson Fok
Chairman of Pedder Clinic
Dr. Manson Fok is a very successful doctor, entrepreneur, and a philanthropist. Dr. Fok is the Founder of the Pedder Clinic, which is one of the largest private medical practices in Hong Kong. Dr. Fok is also the Dean of the Faculty of Health Sciences at the University of Macau (MUST), President of the Macau Healthcare Management and Promotion Association (MHMPA), Vice-Chairman of Chinese Endoscopic Doctors Association, and Vice Director of Specialist Committee for Quality Evaluation of Clinical Endoscopy Diagnosis and Treatment, Department of Medical Service Supervision, Ministry of Health of People’s Republic of China, among many other leadership positions. Dr. Fok received the 2009 “ENDOS Medical Science and Technology Award — International Outstanding Leadership Award in Endoscopy” during the First World Conference and World Endoscopy Expo. Having received his medical degree (MBBS) from the University of Hong Kong in 1982, Dr. Fok was appointed faculty in the Surgical Unit of the University of Hong Kong. Dr. Fok has published many original research papers in high ranking international medical journals and as chapters in various academic books which is focusing on minimally invasive treatment for esophageal surgery. Dr. Fok is actively assisting Kinex to develop an Asian Business Strategy.
Follow Manson Fok:
About Pedder Clinic: Pedder Clinic offers a vast array of surgical specialities including breast surgery, cardiothoracic surgery, colorectal surgery.
Michael Demurjian
Manager, Founder, Chairman & CEO of Aspargo Laboratories
Michael Demurjian is a Manager, Founder, Chairman & CEO of Aspargo Laboratories. He is a successful biotech entrepreneur who has founded and successfully built several technology companies; co-founder of Tyme Inc. (Nasdaq: TYME) a clinical-stage biotechnology company developing metabolic-based cancer therapeutics.
Follow Michael Demurjian:
About Aspargo Laboratories: Aspargo Laboratories commercialize the rights of an oral suspension spray formulation of erectile dysfunction medication Sildenafil citrate.
Rowland Hanson
Chairman of UVLrx Therapeutics
Former Vice President of Worldwide Marketing for Neutrogena Corp. Recruited by Bill Gates at Microsoft where he was Vice President of Corporate Communications and created and executed branding strategy for “Windows,” which he named.
Follow Rowland Hanson:
About eSurface, UVLrx Therapeutics: UVLrx Therapeutics is a biotechnology company that specializes in the fields of medical, healthcare, and therapeutics.
Duke Rohlen
Founder, CEO & Chairman of Ajax Health
Douglas S. Rohlen, also known as Duke, serves as Chief Executive Officer of Ajax Health LLC. Duke Rohlen serves as an Executive Chairman of EPIX Therapeutics, Inc., and has been its Chief Executive Officer. He is a Co-Founder of Ajax Vascular and serves as its Chief Executive Officer. He is a General Partner of D3DC, LLC. He has over two decades of experience in cardiovascular medical devices. He served as the Chief Executive Officer and President at Spirox, Inc. He was a Co-Founder of CV Ingenuity Corp., and served as its President and Chief Executive Officer. He was a Managing Partner of TauTona Group. He served as President of Fox Technologies. He served as Head of Investor Relations at Foxhollow Technologies Inc. He served as President of Strategic Operations at Foxhollow Technologies Inc. Duke Rohlen served as Vice President of Corporate Development and Investor Relations and as Director of Business Development since joining Foxhollow Technologies Inc., he served as President and Chief Executive Officer of Olive Hill Development, a land development company. He served as a Project Consultant at Massachusetts General Hospital. He served as Director of Business Development at LuMend Corporation, a privately-held company that develops chronic total occlusion products in the treatment of peripheral vascular disease which was acquired by Cordis Corporation. In 1999, he served as Entrepreneur in Residence at Alta Partners, a venture capital firm. He served as a Director of Entellus Medical, Inc., Duke Rohlen holds a B.A. in History from Stanford University and an MBA from Harvard Business School.
Follow Duke Rohlen:
About Ablacon, Ajax Health, Atriomx, Cortica, Verix Health: Ajax Health accelerates medical innovation through capital and capabilities.
Jeffrey L. Vacirca
CEO & Chairman of the Board of New York Cancer and Blood Specialists
Follow Jeffrey L. Vacirca:
About AmerisourceBergen, Community Oncology Alliance, ION, New York Cancer and Blood Specialists, North Shore Hematology Oncology Associates, OneOncology, Stony Brook University: New York Cancer and Blood Specialists is delivering state-of-the-art medical technology and world-class cancer care.
Dinesh Butani
Chairman of MediGain
Dinesh Butani is a founding Board Member of MediGain and currently serves as Chairman of the Board. In this role, he leads the Board in all strategic decisions, as well as leading all growth, expansion and service diversification initiatives. Dinesh played an integral role in MediGain being named among Inc. Magazine’s America’s 500 Fastest-Growing Private Companies list in 2009. Dinesh has extensive experience in the Business Process Outsourcing (BPO) Industry; his work in this high growth sector spans nearly 15 years. In addition to serving on MediGain’s Board, he is a Board Director and Founder of several other fast growing BPO companies, including MedSource, Medical Transcription and Document Management, Legacy Health, Healthcare Claims Processing, Quantum Engineering, and Structural Engineering Design. He served as Director of Worldwide Strategic Planning for Denver-based Qwest Communications and for Reston, Va.-based outsourcer Apex Covantage. Additionally, Dinesh was a Vice President of Business Development for North American Engineering Services BPO. Other appointments include the Board of Directors of Dallas-based Chiron Point Investment Fund. Dinesh is a graduate of Purdue University, where he earned a Bachelor of Science in Engineering.
Follow Dinesh Butani:
About : MediGain helps physicians by providing improved back-office processes and enabling more time and resources for patient care.
John C. Staley
Chairman of Hospira
Follow John C. Staley:
About : Hospira is a provider of injectable drugs and infusion technologies.
David Fine
Chairman and Chief Scientific Officer of Vero Biotech
Dr. David H. Fine is the founder and Chairman of Vero Biotech. Dr. Fine served as President of Vero Biotech from inception until December 2011, and then as Chief Executive Officer until August 2013. He has 40 years of experience leading innovation development and transitioning high technology chemistry-based instruments from research through production and into commercialization. In 2000, Dr. Fine co-founded CyTerra Corporation, a company focused on advanced technology for the detection of buried land mines. Dr. Fine served as Chief Executive Officer of CyTerra from 2000 until 2006. Prior to co-founding CyTerra, Dr. Fine worked for 28 years at Thermo Electron Corporation. During his tenure at Thermo Electron, Dr. Fine published extensively on the formation of carcinogenic N-nitrosamines, the detection of NO and NO using chemiluminescence, the detection of explosives for forensic and airport security by converting them to NO, and then measuring the NO, and many other detection systems using the NO moiety. Dr. Fine held various leadership positions at Thermo Electron, including Vice President of Thermedics Inc. and Senior Vice President of Thermedics Detection Inc., both of which were publicly-traded subsidiaries of Thermo Electron. His last assignment at Thermo Electron was as President of Thermo Electron’s R&D Center Inc. From 1969 to 1972. While on the academic staff of the Chemical Engineering Department at MIT, Dr. Fine worked on the formation and mitigation of NO formed in combustion systems and NO related air pollution chemistry. Dr. Fine has published over 100 technical papers in peer reviewed technical literature, including Nature and Science. He is also the inventor on 83 issued U.S. patents, including over 60 patents on NO/NO based chemistry and instrumentation.
Follow David Fine:
About Vero Biotech: Vero Biotech is a biopharmaceutical company developing products to address the medical needs of patients with pulmonary, cardiac diseases.
Omid Moghadam
CEO & Chairman of Ascendant Dx
Omid Moghadam is an inventor and serial entrepreneur with 22 years of experience in commercializing new health technologies. He is the CEO of Ascendant Dx, a firm developing clinical tests based on newly discovered protein biomarkers. Prior to Ascendant he was at Harvard Medical School’s Center for Biomedical Informatics, where he focused on applications of genomics in clinical practice. Previously, he co-founded ventures in genomics (Xovo & Intel Genomics) and electronic health records (Dossia). In the past, he has held executive positions with CGI and Kodak, where he spearheaded innovations in cardiac imaging, cryptography and digital photography. He is Chairman of the Board of Ascendant Dx, and CardioWise, and serves on the board of NanoWatt Design, Osteovantage, and Health-e Pty of Australia and advisory boards of Life Time Health Diary, and Mymee.com. He has served as an advisor to Robert Wood Johnson Foundation, California Healthcare Foundation and Children’s Hospital Boston.
Follow Omid Moghadam:
About Ascendant Dx, Cardiowise, Namida Lab, VIC Technology Venture Development: Commercialize disruptive diagnostic technologies to aid in diagnosis and treatment of diseases of women and children.
Richard White
Chairman of the Board of F2G
Richard has a wealth of experience in infectious disease drug discovery. He spent the first 28 years of his career in the pharmaceutical industry in positions at Lepetit (Italy), Glaxo (UK), Lederle (USA), and at Bristol Myers Squibb in Connecticut, where he was Vice President in charge of Infectious Disease Drug Discovery for 12 years. There he was involved with the discovery/development of the cephalopsporins Cefepime and Cefprozil, and the AIDS drugs Didanosine and Zerit. In 1997 he moved to Biotech taking a position at Versicor in California where he became Chief Scientific Officer. In the ensuing 8 years he played an important role in licensing in and development of Dalbavancin and Anidulafungin, taking Versicor public, merging with Biosearch Italia to create Vicuron, and ultimately in achieving a market capital of 1.9 billion dollars when it was sold to Pfizer in September 2005.
Follow Richard White:
About : F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Stan Abel
Chairman Of The Board Of Directors of SiteOne Therapeutics
Follow Stan Abel:
About SiteOne Therapeutics: SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
Nersi Nazari
Executive Chairman & Founder of VitalConnect
Nersi Nazari is the founder of Pacific General Ventures, an early stage fund, which invests in semiconductor and software companies. Before Pacific General, Nazari was vice president of Signal Processing Technology at Marvell Semiconductor Inc., where his responsibilities included the development of storage and communications products. At Marvell he was directly responsible for the architecture of advanced read channels, Giga bit Ethernet physical layer devices, as well as WLAN products. Additionally, he established the system-on-chip (SOC) family of products for the storage market, the highest revenue family of products at Marvell. From 1994 to 1997, Nazari was chief technologist at GEC Plessey Semiconductor. Before that, he was an engineer at Seagate Technology and Digital Equipment Corp. He holds eight patents. He has a doctorate in Electrical Engineering from the University of Colorado.
Follow Nersi Nazari:
About Pacific General Ventures, VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Bradley E. Patt
Chairman & Chief Executive Officer of TheraCell
Dr. Patt has been chairman of Theracell since it’s inception in 2008 and has served as CEO of the Company since April 2012.
Follow Bradley E. Patt:
About DermOQ, Inc., DxRay Inc., EVO Worldwide, High Beauty, HyVIDA, TheraCell, Thrive Outside The Box: Theracell has two patented platform technologies facilitating stereotactic transplantation of neurons and therapeutic cells into the brain
Daniel Levner
Co-Founder & Chairman of the Scientific Advisory Board of Sight Diagnostics
Daniel Levner is Emulate’s Chief Technology Officer. Prior to joining Emulate’s founding team, he was a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he led the advanced engineering team responsible for developing Emulate’s Organs-on-Chips platform. Levner played a key leadership role in managing the multidisciplinary Organs-on-Chips team by formulating innovative approaches for fostering close collaboration and in-depth exchange between biologists and engineers. Levner brings this tight integration of disciplines to Emulate, where it is a defining part of the company’s culture. Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing tools, and multiplexed analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company, and earlier in his career, an optical telecommunications startup company. Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 20 issued and pending patents.
Follow Daniel Levner:
About Emulate, Sight Diagnostics: Blood diagnostics company that uses machine vision and AI to transform health systems and outcomes through fast and accurate blood testing.
Rong-Hwa Lin
Chairman & CEO of AltruBio
Dr. Lin is founder, CEO and chairman of AbGenomics. To better position the company, Dr. Lin established twin headquarters in both Taipei and San Francisco Bay Area where he and his team can efficiently collaborate with world top talents and key opinion leaders in the medical fields. He is the key inventor of more than a dozen worldwide patents. Under his leadership and well established collaborative culture, the company discovered several promising therapeutic candidates successfully.Prior to joining AbGenomics, Dr. Lin was founding Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin also served as an Associate Editor for Journal of Biomedical Science and a member of the Editorial Board for Int. Immunopharmacology . He received his Diplom, Summa Cum Laude, and Doctor (in Immunology), Magna Cum Laude, degrees from the University of Tübingen in Germany. He has conducted his research works in 3 world renowned institutions: Max Planck Institute for Immunogenetics in Germany, Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University. In his previous academic research journey he has supervised several physicians from different departments to conduct translational researches and published more than 50 refereed papers.
Follow Rong-Hwa Lin:
About AltruBio: AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases.
D. Ronald Yagoda
Co-Founder & Executive Chairman of CyMedica
Ron Yagoda is a Founding investor of OrthAlign, Managing Partner of DryAz Consulting, and Chairman and co-founder of CyMedica Orthopedics, Inc. Mr. Yagoda has 48 years experience as a professional investor and entrepreneur. He is a former member of the New York Stock Exchange (NYSE) and a graduate of The University of Oklahoma, also attending OU Law school. He sits on the boards of University of Oklahoma’s Price College of Business, The Bizzell Memorial Library, DBM Global, Inc., and CyMedica.
Follow D. Ronald Yagoda:
About CyMedica: CyMedica develops and commercializes innovative products that target joint injuries and the resulting muscle atrophy.
Joseph Papa
Chairman of the Board, Chief Executive Officer of Bausch Health
Papa joined Perrigo in October 2006 as President and Chief Executive Officer. Papa was elected as a director in November 2006 and, subsequently, was appointed as Chairman of the Board of Directors in October 2007. Previously, Papa served from December 2004 to October 2006 as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc. Prior to that position, he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. from November 2001 to November 2004. Additionally, Papa has held management positions at DuPont Pharmaceuticals, Pharmacia Corporation, G.D. Searle & Company and Novartis AG. Papa is a director of Smith & Nephew, a developer of advanced orthopedic medical devices.
Follow Joseph Papa:
About Bausch Health: Bausch Health is a develops and markets medications used in the fields of neurology, dermatology and infectious diseases.
Miles Clark
Co-Founder, Chairman of BLUEWAVE Technologies
Miles Clark is the Co-Founder, Chairman at BLUEWAVE.
Follow Miles Clark:
About BLUEWAVE Technologies: BLUEWAVE Technologies develops a rapid disinfection device designed to clean using medical technology.
Estuardo Aguilar-Cordova
Chairman and Chief Executive Officer of Candel Therapeutics
Estuardo Aguilar-Cordova is a co-founder of Candel Therapeutics and has been the chairman and CEO since 2002. He has more than 30 years of experience in the fields of biotherapeutics, cancer research and drug development, including serving as principal or co-investigator in more than 25 clinical trials ranging from Phase I to Phase III. Prior to moving into his role at Candel, Estuardo Aguilar-Cordova held academic positions for nearly two decades. Most recently, he was deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School in Boston and was a faculty member in Pediatrics, Hematology-Oncology at Baylor College of Medicine in Houston. He has served on many national oversight committees, including roles as chairman and member of the NIH Recombinant Advisory Committee (RAC), as a consultant to the FDA Biological Response Modifiers Advisory Committee (BRMAC), and as a member of the Vaccine and Related Products Advisory Committee (VRPAC). Estuardo Aguilar-Cordova has also held other appointments including president of the Latin American Gene Therapy Society. Estuardo Aguilar-Cordova has published more than 80 peer-reviewed scientific publications and book chapters, is on the editorial board of various professional journals and is an inventor on several patent applications. A native of Guatemala, Estuardo Aguilar-Cordova completed his undergraduate studies in Biology at California State University, Bakersfield; Medicine, at Universidad Francisco Marroquín in Guatemala City; and Ph.D. in Molecular Genetics at the University of California at Davis.
Follow Estuardo Aguilar-Cordova:
About Candel Therapeutics: Candel Therapeutics develops cancer immunotherapies designed to improve the lives of cancer patients and their families.
Lawrence C. Best
Chairman of NeoSync
Larry joined Boston Scientific Corporation starting in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. Formerly serving on the Board of Directors of Haemonetics Corp, Larry is currently chairman of OXO Capital LLC, serves on the Board of Directors of Myriad Genetics (NASDAQ:MYGN), and is a founding director of the President’s Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.
Follow Lawrence C. Best:
About Myriad Genetics, NeoSync: NeoSync, Inc. is a clinical stage company That treatment of Major Depressive Disorder.
James E. Muller
Founder & Chief Medical Officer and Chairman of InfraReDx
Dr. James E. Muller has served as Chief Medical Officer and Chairman of the Board of Infraredx since 2011. Dr. Muller’s interest in the causation of coronary events began in 1985 with the discovery of the morning increase of heart attacks. This led to a series of studies on the triggers of coronary events that, together with observations by other investigators, led to formulation of the concept of a “vulnerable” coronary plaque. In 1989, with Drs. Tofler and Stone, Dr. Muller published an article in CIRCULATION defining vulnerable plaques as those at high likelihood of rupture. In 1998, he founded Infraredx to develop spectroscopic technology to identify lipid core plaques, which are suspected to be vulnerable plaques. In 2005, he resigned from his position as Professor of Medicine at the Harvard Medical School to serve as CEO of Infraredx during the development of the scientific foundation of the lipid core plaque instrument. He is the author of over 300 manuscripts related to coronary artery disease, the leading cause of death in the developed world.
Follow James E. Muller:
About InfraReDx: InfraReDx designs and develops intelligent catheter-based coronary imaging devices.
